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SPECIAL REPORT
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ABSTRACT
Introduction: The unparalleled surge in digital health adoption during the COVID-19 pandemic has 
emphasized the potential of mHealth apps. However, the quality of available evidence is generally low, 
and regulatory frameworks have focused on apps with medical purposes only, overlooking apps with 
significant interactions with patients that may require stronger oversight.
Areas covered: To support this expanded evidence generation process, we identified the reasons that 
distinguish mHealth apps compared to medical devices at large and that should differentially feature 
their assessment. mHealth apps are characterized by the iterative nature of the corresponding inter-
ventions, frequent user interactions with a non-linear relationship between technology usage, engage-
ment and outcomes, significant organizational implications, as well as challenges associated with 
genericization, their broad diagnostic potential, and price setting.
Expert Opinion: The renewed reliance experienced during the pandemic and the unprecedented 
injection of resources through recovery instruments can further boost the development of apps. Only 
robust evidence of the benefits of mHealth apps will persuade health-care professionals and benefici-
aries to systematically deploy them. Regulatory bodies will need to question their current approaches 
by adopting comprehensive evaluation processes that adequately consider the specific features of 
mHealth apps.
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1. Introduction
Mobile health (mHealth) apps are defined as software applica-
tions that run on mobile platforms, such as smartphones and 
tablets, and are used to manage health and wellness [1]. With 
over 325,000 units already available on commercial platforms 
as of 2017 [2], mHealth today represents a mature market for 
apps and is projected to grow further, up to a value above 
60 billion U.S. dollars by 2021, with a threefold increase from 
2017 [3]. The COVID-19 pandemic has undoubtedly acceler-
ated this development process, with a 65% growth in mHealth 
app downloads during 2020 globally [4].
That apps may contribute to improve patients’ health and 
quality of life, streamline the delivery process of health-care 
services and reduce the siloed approach based on service 
categories has been reported in the literature [5–7]. 
However, the quality of available evidence is generally low, 
and, above all, there is a lack of clarity as to when and how it 
should be generated and assessed by regulatory and Health 
Technology Assessment (HTA) bodies.
2. Overview of the regulatory landscape for 
mHealth apps
A significant regulatory challenge relates to the extreme diver-
sity of apps in terms of main functions and potential risks to 
users. Just like the US Food and Drug Administration (FDA), 
the EU Medical Device Regulation (MDR) has thus far focused 
on the subset of mHealth apps that can be classified as 
medical devices, i.e. when they are either intended to be 
used as an accessory to a regulated medical device, or trans-
form a mobile platform into a regulated device [1].
Consistently with risk-based classification regulatory sys-
tems [8], the FDA had initially focused its oversight on mobile 
medical apps that present high risks to patients, exercising 
enforcement discretion for products that help patients self- 
manage their conditions or automate simple tasks [1]. With 
the 2017 Digital Health Innovation Action Plan [9], the FDA 
reimagined its regulatory approach by developing a new pro-
gram that should replace the need for a premarket submission 
for certain apps through the pre-certification of digital health 
developers rather than products [10]. The first step of this firm- 
based approach is a pilot program that has so far involved 
nine companies, including Apple and Fitbit [11].
At the European level, in view of the implementation of the 
new MDR and In-Vitro Diagnostics Regulation (IVDR) in 
May 2021, the Medical Device Coordination Group (MDCG) 
has issued guidance concerning evidential requirements for 
Medical Device Software (MDSW), focusing on software 
(including apps) with medical purposes only [12,13]. 
According to this guidance, evidence generation must be 
consistent with the level of risk of MDSW and must follow 
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the same rules applicable to any other medical devices or 
in vitro diagnostics, as set out in the MDR and IVDR.
However, as the MDCG’s guidelines mostly refer to the 
work done by the International Medical Device Regulatory 
Forum, the mobile medical apps actually covered by the gui-
dance, except for limited cases, are not meant to provide 
direct contact with patients and are instead aimed to inform 
or drive clinical management and the diagnostic or therapeu-
tic process [14]. In contrast, other available apps are intended 
to elicit behavior change, enhance adherence with treatment, 
deliver disease-related education or act as standalone digital 
therapeutics [15], all functionalities that need a significant 
interaction with patients and highlight the challenges to 
keep up with an evolving and diversified spectrum of apps 
by the current regulation [16]. It is having also and especially 
these potentially non-medical mHealth apps in mind that an 
expanded review policy could be implemented by regulatory 
bodies [11]. To support this expanded evidence generation 
process, we aim at clarifying the distinguishing features of 
mHealth apps and the associated challenges that would be 
encountered in their assessment.
3. What does make apps assessment more 
challenging?
Drummond et al. described six reasons that mark a difference 
between drugs and medical devices when assessment is at 
stake [17]. These equally apply, and are often emphasized, in 
the case of mHealth apps indicating the need for a distinction 
between the assessment process of medical devices at large 
and that to be implemented for apps.
First, just as it happens for some medical devices, evidence 
generation through randomized controlled studies (RCTs) is 
extremely challenging for mHealth apps. The incremental nature 
of technological development of MDs makes RCTs, in some 
cases, unsuitable to demonstrate efficacy, and therefore alterna-
tive or additional types of studies have been suggested (e.g. real- 
world evidence) [8]. Experimental studies are even more widely 
inapt for mHealth apps, that can evolve very rapidly, incorporate 
continuous measurement of the intervention effects, and need 
to be constantly readjusted just to keep up with their intended 
use [18]. The adaptive nature of apps can go as far as to the 
possibility of tailoring the intervention components to individual 
end-users’ characteristics and personalizing them in real time 
[19]. This perpetual beta state of mobile software is not only an 
inherent feature but also a requirement to adapt to the changing 
contextual circumstances which may at any time reverse the 
effectiveness of the intervention. Moreover, apps typically deliver 
complex interventions in terms of components, outcomes, and 
causal pathways [20,21]. For instance, apps containing gamifica-
tion elements were found to include a median of 14 different 
behavior change techniques (BCTs) [22], which interact among 
them and may evolve as a result of technology or scientific 
advancement. Each intervention may go as far as changing the 
behaviors of other family members other than the initial target 
only, and the impact on outcomes may be influenced by several 
different mediators and moderators. As such, the typical positi-
vistic assumptions underpinning RCT study designs, based on 
a supposed causal relationship between the intervention and the 
outcomes of interest, are challenged in the context of app 
evaluations [23] by the host of mechanisms of change attainable 
through mHealth apps inherently linked to the social environ-
ment [21]. New features that are more suitable for digital tech-
nologies and possibly provide a better understanding of within- 
subject differences have been proposed, including model-based 
designs of adaptive research, the use of factorial designs to 
assess the effectiveness of single intervention components, opti-
mization strategies borrowed from engineering or other data- 
intensive domains, and the use of predictive modeling [19,24,25], 
up to additional solutions to increase the efficiency of traditional 
RCTs [26]. Nonetheless, the overwhelming majority of the few 
peer-reviewed studies are still adopting the RCT as the preferred 
design for the evaluation of mHealth apps [27].
Second, as for some medical devices and as noted in the 
previous paragraph, mHealth apps’ efficacy depends not 
only on the product itself but also on how it is used. 
While for medical devices (e.g. implantable medical devices) 
these user characteristics mainly refer to the health-care 
professionals’ learning curve in administering them, in the 
case of apps the interventions are often directly managed 
by patients themselves. From an ‘embodied technology’ in 
the case of drugs [17], we have now moved toward a fully 
‘interactive technology,’ where not only different individuals 
may develop different forms of interplay with the app, but 
the relationship between technology usage, engagement 
and outcomes is often non-linear [24]. This entails that 
effective engagement can only be defined individually and 
that the same level of utilization (in terms of access metrics) 
may generate different outcomes according to individual 
characteristics, target groups, and interventions. Whilst it is 
beyond dispute that the individual level of engagement 
with the app can produce decisive effects on outcomes, 
this makes the evidence generation process even more 
complex. On top of generating the right level of engage-
ment individually, the challenge with apps is to sustain it 
longitudinally. Retention is to mHealth apps as adherence is 
Article highlights 
● mHealth apps are extensively available on commercial platforms, but 
are often not supported by adequate clinical and economic evidence
● Just like in the US, the regulatory guidance issued at the European 
level has focused on apps with explicit medical purposes only, 
neglecting many apparently lower-risk apps that have significant 
interactions with patients and may cause harm to users if not 
properly regulated
● Expanded evidence generation is needed to support the consolida-
tion of mHealth apps in the healthcare realm and should account for 
their distinguishing features compared to other healthcare 
technologies
● In the case of mHealth apps, the characteristics that differentiate 
medical devices from drugs are often emphasized and raise addi-
tional challenges for their evaluation
● Apps typically deliver complex interventions because of their adap-
tive nature, the coexistence of several potential mechanisms of 
change, the patient centricity in the development and delivery of 
the technology, as well as the context-specific implications that limit 
the transferability of observed results
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to chronic pharmacological treatments, and is indeed one of 
the most significant issues for any eHealth intervention [28], 
as only small portions of users show consistent access to 
mHealth apps over time [29]. To foster retention and lever-
age in this revamped patient centricity, user-centered 
designs must be embraced to anticipate users’ needs in 
the development phase and make sure finalized interven-
tions are responsive to stated preferences. Despite several 
alternative design methods of mHealth apps have been 
proposed [30], only positioning the patient as a constant 
partner in the development process of mHealth apps could 
offer insights that may substantially improve the health-care 
outcomes for patients and providers [31].
Third, app implementation has the potential to generate 
relevant organizational implications, possibly wider than any 
other medical device. The digital nature of mHealth apps can 
radically transform how the delivery process of health-care 
services is organized within health-care centers. Let us think 
about enhanced data sharing and the possibility for different 
types of health-care professionals in different patient care 
settings to receive, at the same time, information on patients’ 
symptoms and outcomes so as to enact integrated care pro-
tocols and services. The wide organizational implications of 
app adoption are usually context-specific, meaning that 
change management processes adopted in a single institution 
can seldom be transferred to another and all analyses should 
be performed considering the specific organizational and cul-
tural backgrounds [32]. In this respect, Bluestar, the first app to 
receive the FDA approval as a mobile prescription therapy for 
diabetes self-management [33] based on preliminary studies 
[34,35], showed no effect on glycemic control in a later prag-
matic multisite implementation, highlighting the importance 
of contextual factors, such as site readiness and training activ-
ities, in determining app effectiveness [36].
This leads us to the fourth additional challenge. ‘Genericization’ 
is theoretically attractive but practically seldom possible for apps. 
Regulatory bodies adopt the concept of substantial equivalence to 
streamline the regulatory process for medical devices. When MDs 
present the same characteristics of a predicate (i.e. another device 
with the same intended use already approved), manufacturers do 
not need to produce any additional evidential requirement and 
access to market is expedited. Resorting to substantial equivalence 
may seem straightforward for mHealth apps, particularly given the 
exceptional number of legally different products that seemingly 
share comparable technological features and behavior change 
techniques (when applicable). These class effect recommenda-
tions are nonetheless hardly applicable to mHealth apps consider-
ing that: i) their success significantly depends on the 
organizational adjustments that are necessarily local and 
grounded in the implementation process; ii) it is particularly chal-
lenging to achieve a detailed specification of any mHealth app 
intervention and its components [18], given the continuous evolu-
tion and the possibility to tailor several components to individual 
needs and preferences. As such, even apps designed for the same 
target population with comparable functionalities and mechan-
isms of action may generate differential outcomes due to appar-
ently insignificant differences in design processes, observed 
usability, professional acceptability, and integration with human- 
led components.
Compared to medical devices at large, apps may also have 
diagnostic potential by gauging signs and symptoms directly 
from lay people (i.e. patients and their caregivers). In terms of 
app evaluation, this produces an additional need to assess and 
certify these inputs’ reliability and the methods applied to 
collect them, which may generate valuable insights but also 
significant challenges by leveraging on the growing amount 
of available data [37]. Further evaluation implications are sym-
metrical to what was previously emphasized for medical 
devices: the need to account for the value resulting from the 
treatment that follows diagnosis, and to appreciate apps’ 
indivisibility across multiple potential applications.
Finally, prices for medical devices are more likely to fluc-
tuate over time compared to those for drugs. In the case of 
apps, since advanced jurisdictions are starting to pilot pre-
scription mechanisms just now [38], there are no consolidated 
procurement mechanisms, yet. Unit prices for subscription to 
individual apps should be negligible (think of commercially 
available apps’ fees as a benchmark), but to date, vendors 
have instead marketed their apps as an add-on service 
attached to a drug or a medical device. Of course, there are 
differences expected for standalone digital therapeutics but, if 
the paradigm of apps as an enhancement of currently avail-
able therapies will persist, the merging of apps with their 
originating technology will continue to generate extra chal-
lenges from a clinical and economic evaluation standpoint, 
making it difficult to predict the future trend in terms of 
pricing. Furthermore, price setting is challenging for mHealth 
apps also for reasons associated with costs. First, like most 
digital interventions, apps can rapidly change scale at minimal 
incremental cost compared to traditional technologies. 




- Adaptive nature of apps makes experimental studies 
inapt
- Complexity of app-based interventions in terms of 
components, outcomes and causal pathways
- Non-applicability of positivistic assumptions
II. Interaction - Efficacy depends on the way apps are used
- Effective engagement is strictly individual
- Retention rates significantly decrease longitudinally
III. Organizational 
implications
- Change management processes are typically context- 
specific
- App-related evidence has limited transferability
- Organizational readiness and connected human-led 
components may influence app effectiveness
IV. Genericization - Substantial equivalence is hardly applicable to 
mHealth apps
- App interventions cannot be locked down due to 
their continuous evolution
- Despite similar features and target populations, 
different apps may generate differential outcomes
V. Diagnostic 
potential
- Potential inputs by lay people and associated need to 
certify their reliability
- Value of improved diagnosis needs to also account 
for the associated improvement in clinical outcomes
- Need to weigh all potential diagnostic applications of 
any mHealth app
VI. Pricing - No consolidated procurement mechanisms as 
a guideline
- Different cost structures compared to traditional 
healthcare technologies
- Plurality of possible marketing approaches (add-on 
service vs standalone technology)
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Second, the cost structure of apps is different from the ones of 
commonly fixed products in the pharma and device industries: 
while research costs may be significantly lower compared to 
drugs and devices, the initial outflows for development, 
design and their multifold iterative steps are not negligible 
and must be accurately captured. Third, specific costs asso-
ciated with app interventions include the promotional costs to 
push the intervention uptake to secure that ‘effective engage-
ment’ is reached and to sustain it longitudinally [24]. However, 
cost-effectiveness analyses of mHealth apps have rarely been 
performed and the related evidence is still scant [39]. Table 1 
synthesizes the six analyzed domains and the associated chal-
lenges that distinguish the assessment of mHealth apps.
4. Conclusion
As it was done for the comparison between medical devices 
and drugs [17], we have envisaged the reasons why the 
assessment of mHealth apps is more challenging than that 
of traditional medical devices.
To date, mHealth apps have not lived up to the same 
evidence standards in place for drugs and devices. This is 
partially attributable to the inability to appreciate their distinc-
tive features that have significant implications for clinical and 
economic evaluations. While early-stage evidence generation 
during the product development process may be enough to 
convince ‘early adopters’ [25], only robust evidence of benefits 
will persuade the majority of potential beneficiaries, as well as 
payors, to adopt mHealth app systematically.
Despite many have supported the case for digital excep-
tionalism [40], this should not turn into a generalized amend-
ment for mHealth apps, whose future deployment cannot be 
justified through social enthusiasm, economic circumstances, 
and political expediency only but should anyway be sup-
ported by robust evidence [41].
5. Expert opinion
Europe is the jurisdiction with the highest number of mHealth 
apps manufacturers (34%) globally [42], with a great propor-
tion of these apps likely to be characterized by a significant 
interaction with patients. As proof of this, the mobile health 
categories that were thought to carry the best global market 
potential 5 years ago were indeed remote monitoring (32%), 
diagnostic apps (31%), and medical condition management 
(30%) [43]. Furthermore, the COVID-19 pandemic has laid bare 
the inadequacies of analog health-care systems and show-
cased the benefits of a digital health.
Accordingly, ‘digitilisation’ is among the top priorities of 
Next Generation EU [44], the €750 billion recovery instrument 
agreed on at the European level to support the recovery and 
make Europe, among others, more digital, potentially boost-
ing the development of mHealth and apps further. Many EU 
countries will thus receive an unprecedented injection of 
resources to invest in a better society and economy for 
future generations. Health will undeniably be at the heart 
of these changes, as COVID-19 has clearly shown that with-
out a healthy population we cannot achieve a wealthy 
society.
To make the most of this potential for mHealth apps, 
a shared effort is necessary. Regulatory and HTA bodies 
would need to expand their current regulation of health 
apps and consider their specific features in their guidance to 
avoid that assessment processes and procedures developed 
with traditional MDs in mind are applied tout court to new, fast 
evolving products. If inadequately regulated, the future 
deployment of mHealth apps can be threatened either way: 
too few will access the market (e.g. if RCTs will become the 
rule to generate evidence) thus diluting the huge potentials to 
increase patients’ outcomes and (sometimes) reduce health- 
care costs; or too many (e.g. if blurred boundaries persist 
between what must and must not be regulated) will flood 
the market with unchecked effectiveness on patients’ health 
and quality of life, and poor retention rates darkening the 
future of this high-potential industry.
In regards to the evaluation for HTA purposes, the National 
Institute for Health and Care Excellence in the UK has recently 
adopted a more comprehensive approach and defined effec-
tiveness and economic impact standards for all Digital Health 
Technologies (DHTs), by stratifying them into evidence tiers 
based on their main clinical function and corresponding risk 
levels [45]. This and other experiences can be streamlined by 
the European network of HTA agencies (EUnetHTA), especially 
in view of the new EU HTA regulation that will likely come into 
force this year.
In this scenario, decision makers and regulators should also 
be supported by non-governmental actors, that could foster 
emerging industry standards and rigorously review the numer-
ous rating scales and frameworks that are the subject of 
a vivid scientific debate [46].
The future of mHealth apps will also depend on how, 
besides the regulatory and HTA bodies, health-care providers 
and professionals will respond to procurement and organiza-
tional implications of their utilization. Once market authoriza-
tion has been granted and efficacy has been checked, 
mHealth apps would need to be incorporated into routine 
practice to deliver their full potential and this can happen 
only under certain conditions. First, new models of organizing 
the production and delivery of health-care services must be 
developed. mHealth has the potential to bridge the silos and 
connect different settings of care, substantially contributing to 
an integrated, cross-cutting care approach. Second, conven-
tional procurement activities must develop into value-based, 
innovative practices aimed at assessing the added value of 
mHealth apps, especially when it is entangled in another 
technology. From the above, it follows that the conventional 
fee-for-service reimbursement schemes poorly capture the 
value of mHealth and other payment structures that offer 
greater flexibility need to be developed.
With more smartphones (8.3 billion subscriptions in 2019) 
than people on the planet (7.7 billion in 2019) [47], mHealth 
will definitely represent the main driver of the digital health 
revolution over the next years. What is less certain is the time 
needed for health-care systems to adapt to a new combina-
tion of analog and mobile services: this will mainly depend 
upon the degree of flexibility provided by health-care organi-
zations and health-care professionals. No matter how we reach 
this new equilibrium, it is fundamental that none is left behind 
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by the digital revolution as it happened with analog systems 
for several youth and adult chronic patients during the COVID- 
19 pandemic [48–50]. If mHealth could eliminate geographical 
distances, it can, at the same time, marginalize deprived social 
classes if left unregulated [51].
A lot is at stake in the case of mHealth apps. Decision 
makers and regulatory bodies should extend their review 
beyond apps intended for medical use only. Adequate evalua-
tion processes that take into account the inherent specificities 
of this class of health-care technologies will enhance the like-
lihood that the full potential of mHealth apps can be realized 
in the foreseeable future.
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